Canadian application, no grantCanada
Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
CA 2405233 A1 · Owner: Merck Frosst Canada & Co./Merck Frosst Canada & Cie · Inventors: Jones, Thomas R.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Prostaglandin D2 receptor antagonists in conjunction with an antihistamine and/or a leukotriene antagonist are useful in the treatment of allergic conditions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 9, 2001
GrantedNo grant recorded
Term endedApril 9, 2021
Patent numberCA 2405233 A1
Classification (IPC)A61K45/06 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.